KemPharm (NASDAQ:KMPH) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.46), Fidelity Earnings reports.
KMPH traded down $0.03 during mid-day trading on Wednesday, hitting $1.17. 80,113 shares of the stock were exchanged, compared to its average volume of 191,928. KemPharm has a 1-year low of $1.15 and a 1-year high of $7.15. The firm has a market cap of $32.54 million, a price-to-earnings ratio of -0.47 and a beta of 1.63.
KMPH has been the topic of several recent analyst reports. Zacks Investment Research lowered KemPharm from a “hold” rating to a “sell” rating in a research note on Tuesday, January 15th. ValuEngine lowered KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. KemPharm has an average rating of “Hold” and a consensus price target of $10.75.
An institutional investor recently raised its position in KemPharm stock. Geode Capital Management LLC increased its position in shares of KemPharm Inc (NASDAQ:KMPH) by 136.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,047 shares of the specialty pharmaceutical company’s stock after acquiring an additional 98,775 shares during the period. Geode Capital Management LLC owned about 0.65% of KemPharm worth $304,000 at the end of the most recent quarter. 34.30% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2019/05/15/kempharm-kmph-releases-quarterly-earnings-results-meets-estimates.html.
KemPharm Company Profile
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
Read More: What causes a recession?
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.